Literature DB >> 2890676

Benzodiazepine dependence.

R P Swinson1, J C Pecknold, M E Kirby.   

Abstract

Benzodiazepines (BDPs) are widely used drugs that are effective in controlling the symptoms of anxiety. Tolerance develops rapidly to some of the effects but not to anxiolytic effect in most patients. Dependence occurs at usual therapeutic doses and in a small proportion of patients is accompanied by an enormous increase in the dose taken. The majority of subjects using very high doses are dependent on other substances concurrently. On discontinuing BDPs patients may suffer from relapse of the original condition, rebound in the severity of the symptoms of the original condition or the onset of new symptoms in an abstinence syndrome. If BDPs are discontinued abruptly there may be severe consequences such as seizures. With tapering of the dose, even if this is rapid and from high dose, high potency BDP, the subject will probably experience considerable discomfort but rarely life-threatening effects. Whilst there is concern that BDPs are used too freely, the conditions treated are accompanied by significant morbidity and mortality. The prevalence of pure BDP dependence is low and it is still a matter of debate as to how often BDPs should be prescribed, for which conditions and for what length of time.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2890676     DOI: 10.1016/0165-0327(87)90016-4

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  3 in total

Review 1.  A risk-benefit assessment of buspirone in the treatment of anxiety disorders.

Authors:  J C Pecknold
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

2.  Effects of legal and illegal use of benzodiazepines at acute admission to a psychiatric acute department.

Authors:  John C Fløvig; Arne E Vaaler; Gunnar Morken
Journal:  BMC Res Notes       Date:  2010-10-19

3.  Changes in "withdrawal symptoms" following discontinuation of low-dose diazepam.

Authors:  P Hayward; J Wardle; A Higgitt; J Gray
Journal:  Psychopharmacology (Berl)       Date:  1996-06       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.